MeSH tree: C15.604.515.560
Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects over time, according ...
May 26, 2026
0
5
A deadly form of leukemia may be stopped before it ever develops by introducing targeted maternal screening in the United States, according to new research. The national study, led by physician-scientists at Sylvester Comprehensive ...
Apr 30, 2026
0
6
Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia Laboratory have developed a data-sharing platform that unites genomics, gene expression and clinical information ...
Apr 6, 2026
0
4
Scientists at the University of Utah (the U) have developed a new "lab-on-a-chip" device that uses artificial intelligence to rapidly predict cancer cell sensitivity to targeted therapies for children with T-cell acute lymphoblastic ...
Mar 27, 2026
0
13
New research from the University of Minnesota School of Dentistry and Masonic Cancer Center is providing important new insights into the structure of a human virus that causes blood cancer. In their study published in Nature ...
Feb 16, 2026
0
28
Researchers at Kumamoto University have uncovered a previously unknown molecular mechanism by which human T-cell leukemia virus type I (HTLV-1) drives the development of adult T-cell leukemia-lymphoma (ATL), one of the most ...
Jan 5, 2026
0
14
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory ...
Dec 10, 2025
0
11
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine ...
Dec 9, 2025
0
6
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare ...
Dec 8, 2025
0
48
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
Dec 8, 2025
0
13
